Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Pacific Edge’s Cxbladder Detect Outperforms Other Diagnostic

Research Shows Pacific Edge’s Cxbladder Detect Outperforms Other Non-Invasive Bladder Cancer Diagnostics

Dunedin, NZ and Hershey, PA (May 25, 2015): Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used tests was published online this week in the peer-reviewed Open Access medical journal BioMed Central (“BMC”)

Medical Research Methodology. http://www.biomedcentral.com/1471-2288/15/45
. Pacific Edge, a New Zealand-headquartered global cancer diagnostics company with U.S. subsidiary, Pacific Edge Diagnostics USA, in Hershey, PA, developed and markets Cxbladder.

“The published research reviewed the performance of Cxbladder Detect versus other available non-invasive test methods, based on data from 939 patients and 5 clinical trials, and showed Cxbladder Detect to outperform those methods, including the UroVysion® FISH assay that is widely used in the United States in conjunction with standard procedures in the urlogical work-up for bladder cancer,” said David Darling, Pacific Edge Chief Executive Officer. “These new findings favourably position Cxbladder Detect as the leading non-invasive bladder cancer diagnostic tool in terms of its relative performance (high sensitivity, high signal-to-noise, and low cross-validation error rate).” The other non-invasive test methods included in the comparison were cytology and NMP22.

(Ms.) Jackie Walker, Chief Executive Officer for Pacific Edge Diagnostics USA, said, “These results should be highly relevant for both urologists and US payer organizations who provide reimbursement for cancer diagnostic tests. This publication is the first piece of comparative data that includes UroVysion® FISH, a molecular test that is widely used by clinicians and physicians in the US and reimbursed by most major payers.”

“This and other recent peer-reviewed publications demonstrating the superiority of Cxbladder represent key elements in our company’s strategy of delivering physicians a one-stop shop for bladder cancer detection with high performance Cxbladder products in conjunction with standard procedures for bladder cancer detection and surveillance,” concluded David Darling.

ABOUT Cxbladder Detect

Cxbladder Detect is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of urine.

Cxbladder Detect is commercially available in New Zealand, Australia and the USA. Cxbladder Detect is available in the USA and NZ as a laboroatory Developed Test (LDT) from the company’s CLIA certified laboratories, providing physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with a reliable adjunct to cystoscopy. The Cxbladder Detect cancer detection test has been validated by a multicentre, international clinical study. www.Cxbladder.com

ABOUT Cxbladder Triage

Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic biomarkers to accurately identify and remove patients with haematuria who have a low probability of bladder cancer, from needing to have a full-urological work-up.

This is a tool for use by clinicians and physicians in the primary evaluation and is intended to reduce of the number of patients needing a full expensive and invasive work-up for urothelial cancer. www.Cxbladder.com

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 


Science Media Centre: Understanding DDoS cyber attacks – Expert Reaction

Cyber attacks have hit several New Zealand organisations this month, disrupting their online services. The Distributed Denial of Service (DDoS) attacks were the same kind of cyber attack that affected the NZX around this time last year... More>>


Financial Markets Authority: Spike in investment scam complaints since COVID

The Financial Markets Authority (FMA) - Te Mana Tātai Hokohoko – is warning New Zealanders to be on the lookout for three unique types of scams that have been on the rise since the start of COVID-19. The warning comes as the FMA responds to a rise in complaints about investment scams and fraud lodged with the regulator in the first half of this year... More>>


Statistics: Strong export growth narrows current account deficit to $3B

The seasonally adjusted current account deficit narrowed to $3.0 billion in the June 2021 quarter, Stats NZ said today. The current account deficit was $2.2 billion narrower than the previous quarter due to an increase in value of goods exports (up $1.4 billion) and services exports (up $1.7 billion... More>>




Statistics: GDP rises in the June 2021 quarter

Gross domestic product (GDP) rose by 2.8 percent in the June 2021 quarter, following a 1.4 percent increase in the March 2021 quarter, Stats NZ said today. June 2021 quarter GDP was 4.3 percent higher when compared with the December 2019 quarter... More>>


Energy-from-waste: $350 Million Plant To Deliver Renewable Energy Considered

Investigations have begun into the viability of building an Energy-from-Waste plant that will safely convert 350,000 tonnes of waste, that would otherwise be dumped into South Island landfills annually, into renewable electricity... More>>

Olam: Confirms plans for commissioning of NZ dairy plant

OFI, a global leader in natural and sustainable food ingredient solutions, today confirmed plans to develop a new dairy processing facility at Tokoroa. It is now taking expressions of interest from potential farmer suppliers, employees, contractors, and general trade suppliers... More>>